Next Oncology

学者数9

论文数9

被引数0

关联论文 (9)

发表时间

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer 对RAS(ON) 多选择性抑制剂daraxonrasib的获得性耐药性指导胰腺癌的合理联合治疗策略

Nature Medicine

IF50

2026-08-11

OAAI

Ida Aronchik; Sumit Kar; Yongxian Zhuang; Ethan Ahler; Lick Pui Lai; Vidya Seshadri; Yu Chi Yang; Ashenafi Bulle; Marie Menard; Biswadeep Nayak; Mark P. Labrecque; Julien Dilly; Eejung Kim; Lingyan Jiang; Jason Yano; Urszula N. Wasko; Ciara Helland; Sean Bredeson; Brett Garrick; Yevgeniy Gindin; Brad Sickler; Xing Wei; Kyle Seamon; Jingjing Jiang; Kian-Huat Lim; Matthew Holderfield; Elsa Quintana; Aparna Hegde; Zeena Salman; Alexander Starodub; Alexander Spira; Wungki Park; David S. Hong; Minal Barve; Meredith Pelster; David Sommerhalder; Salman R. Punekar; Ignacio Garrido-Laguna; Brian M. Wolpin; Anirban Maitra; W. Clay Gustafson; Steve Kelsey; Jacqueline A. M. Smith; Kevin K. Lin; Andrew J. Aguirre; Mallika Singh

TPRG-05 A FIRST-IN-HUMAN STUDY OF A CNS-PENETRANT, SELECTIVE ERBB2 INHIBITOR, CGT4255, IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH ERRB2 GENETIC ALTERATIONS OR HER2 OVEREXPRESSION TPRG-05 CGT4255作为中枢神经系统穿透性、选择性ERBB2抑制剂在具有ERBB2基因改变或HER2过表达的晚期实体瘤患者中的首次人体研究

Neuro-Oncology Advances

IF4.1

2026-08-07

OAAI

Sarah Goldberg; Muhammad Rizwan Khawaja; Jose Pacheco; Jeffery Russell; Joshua Sabari; Dena Westphalen; Wen-Ling Kuo; Meredith Little; Kevin Moynihan; Kathleen Dorris; Mohamad Adham Salkeni

HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results HPK1抑制剂NDI-101150单药治疗及联合帕博利珠单抗治疗晚期实体瘤患者的Ⅰ/Ⅱ期试验结果

Cell Reports Medicine

IF10.6

2026-05-06

OAAI

David A. Braun; Marcus S. Noel; Ryan H. Moy; Kurt Demel; Martin Gutierrez; Sunil Sharma; Arif Hussain; Shirish Gadgeel; Julio Peguero; Toni K. Choueiri; Hamid Emamekhoo; Brian Van Tine; Rama Balaraman; GiNell Elliott; Sritama Nath; Scott R. Daigle; Pavan Kumar; Anita Scheuber; David Sommerhalder

Evaluation of Dronabinol to Decrease Opioid Use for Cancer-Induced Bone Pain 评估大麻二酚减少癌症诱发性骨痛中阿片类药物使用的效果

The Oncologist

IF0

2026-04-28

OAAI

Jennifer Segar; Kiah Farr; Mary Junak; Denise Roe; Sima Ehsani; Mohab Ibrahim; Todd W Vanderah; Pavani Chalasani; null

A phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors 一项关于modakafusp alfa单药及联合pembrolizumab治疗晚期或转移性实体瘤的Ib/II期研究

Frontiers in Oncology

IF3.3

2025-12-09

OAAI

David Gill; Charles L. Cowey; Gregory A. Daniels; David Sommerhalder; Raghad Abdul-Karim; John M. Kirkwood; Joanna Kolodney; Inderjit Mehmi; Rachel Roberts-Thomson; James Strauss; Sajeve Thomas; Eric Whitman; Yan Xing; Meredith McKean; Sabrina Collins; Cheryl Li; Gurpanna Saggu; Tian Chen; Shining Wang; Marina Lewis; Xavier Parot; Melissa Johnson

YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial YAP/TEAD抑制剂VT3989在实体瘤中的研究：一项1/2期临床试验

Nature Medicine

IF50

2025-10-19

PREAI

Timothy A. Yap; David J. Kwiatkowski; Ibiayi Dagogo-Jack; Michael Offin; Marjorie G. Zauderer; Robert Kratzke; Jayesh Desai; Amy Body; Michael Millward; Anthony W. Tolcher; Kanwal P. S. Raghav; Archie Thurston; Len Post; F. Andrew Dorr; Tracy T. Tang; Yufeng Li; Neelesh Sharma; Hedy L. Kindler

Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism AMXT 1501二癸酸酯与二氟甲基鸟氨酸联合用药的I期剂量递增试验：一种靶向免疫抑制性多胺代谢的双药策略

ESMO Open

IF8.3

2025-09-06

OAAI

S.A. Piha-Paul; A.W. Tolcher; A.L. Vandross; A.I. Spira; M.R. Burns

Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study HH2853（一种新型EZH1/2双抑制剂）在难治性实体瘤或非霍奇金淋巴瘤患者中的安全性与有效性：一项I期研究

eClinicalMedicine

IF10

2025-08-07

OAAI

Zhengfu Fan; Jin Wang; Dan Liu; Lin Shen; Meiyu Fang; Patrick Johnson; Han Tun; David Sommerhalder; Jilong Yang; Yun Yang; Javier Munozi; Jun Zhu; Tian Gao; Zhiming Li; Xian'an Li; Qiuying Ma; Chao Lv; Songda Yu; Fugen Li; Yuqin Song; Jifang Gong

Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study PHranceSCa研究中，HER2阳性早期乳腺癌患者皮下注射固定剂量组合的帕妥珠单抗和曲妥珠单抗的长期安全性与有效性：一项随机、开放标签的II期研究

Clinical Breast Cancer

IF2.5

2025-05-03

PREAI

Joyce O'Shaughnessy; Susana Sousa; Josefina Cruz; Dame Lesley Fallowfield; Päivi Auvinen; Catarina Pulido; Ana Cvetanovic; Sharon Wilks; Leonor Ribeiro; Mauricio Burotto; Thomas Boulet; Valentine Revelant; Nathalie Theron; Peter Trask; Laurentia Wahyudi; Zuzana Kirchmayer Machackova; Ljiljana Stamatovic